Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Diabetes Obes Metab. 2019 Mar;21(3):479-490. doi: 10.1111/dom.13561. Epub 2018 Nov 20.
Obesity is a global pandemic with immense health consequences for individuals and societies. Multiple factors, including environmental influences and genetic predispositions, are known to affect the development of obesity. Despite an increasing understanding of the factors driving the obesity epidemic, therapeutic interventions to prevent or reverse obesity are limited in their impact. Manipulation of the human gut microbiome provides a new potential therapeutic approach in the fight against obesity. Specific gut bacteria and their metabolites are known to affect host metabolism and feeding behaviour, and dysbiosis of this biosystem may lead to metabolic syndrome. Potential therapies to alter the gut microbiota to treat obesity include dietary changes, supplementation of the diet with probiotic organisms and prebiotic compounds that influence bacterial growth, and the use of faecal microbiota transplant, in which gut microbiota from healthy individuals are introduced into the gut. In this review, we examine the growing scientific evidence supporting the mechanisms by which the human gut microbiota may influence carbohydrate metabolism and obesity, and the various possible therapies that may utilize the gut microbiota to help correct metabolic dysfunction.
肥胖是一种全球性的流行疾病,对个人和社会都有巨大的健康影响。已知多种因素,包括环境影响和遗传易感性,会影响肥胖的发展。尽管人们越来越了解导致肥胖流行的因素,但预防或逆转肥胖的治疗干预措施的效果有限。人类肠道微生物组的操纵为对抗肥胖提供了一种新的潜在治疗方法。已知特定的肠道细菌及其代谢物会影响宿主的新陈代谢和进食行为,而这种生物系统的失调可能导致代谢综合征。改变肠道微生物组以治疗肥胖的潜在疗法包括饮食改变、用益生菌和影响细菌生长的益生元化合物补充饮食,以及使用粪便微生物移植,即将健康个体的肠道微生物引入肠道。在这篇综述中,我们研究了越来越多的科学证据,这些证据支持人类肠道微生物组可能影响碳水化合物代谢和肥胖的机制,以及可能利用肠道微生物组帮助纠正代谢功能障碍的各种可能的治疗方法。
Diabetes Obes Metab. 2018-11-20
J Am Assoc Nurse Pract. 2020-7
Hormones (Athens). 2017-7
Gastroenterol Clin North Am. 2016-12
Lancet Gastroenterol Hepatol. 2017-8-24
Front Immunol. 2018-9-10
Expert Rev Gastroenterol Hepatol. 2021-10
Int J Mol Sci. 2025-6-29
Front Endocrinol (Lausanne). 2025-6-19
Biomedicines. 2025-5-31
Nutrients. 2025-5-18
Front Microbiol. 2025-5-2
Probiotics Antimicrob Proteins. 2025-5-16
Commun Biol. 2025-4-2
Therap Adv Gastroenterol. 2025-2-23